Real-World Use of Fedratinib for Myelofibrosis Following Prior Ruxolitinib Failure: Patient Characteristics, Treatment Patterns, and Clinical Outcomes

This study examined real-world patient characteristics, treatment patterns, and clinical outcomes of patients with MF treated with fedratinib following ruxolitinib failure in US clinical practice.

Source: Clinical Lymphoma, Myeloma and Leukemia - September 28, 2023 Category: Hematology Authors: John Mascarenhas, Claire Harrison, Tammy A. Schuler, Djibril Liassou, Marn é Garretson, Taavy A. Miller, Sankar Mahadevan, Ali McBride, Derek Tang, Irene S. DeGutis, Pranav Abraham, Jonathan Kish, Bruce A. Feinberg, Aaron T. Gerds Tags: Original Study Source Type: research